Mises Daily
Author:
Dale Steinreich
Online Publish Date:
First it was Martha Stewart. The imbroglio began last December, when ImClone Systems Incorporated (NasdaqNM: IMCL) was unable to obtain a U.S. Food and Drug Administration (FDA) review of its application to sell its newly developed treatment for colon cancer, Erbitux. The FDA appears to have first given the news of its denial to the brother of